Online
Browse
Drugs
Starred Drugs
Categories
Pathways
Drug Reactions
Drug Classification
Drug Targets
Pharmaco-genomics
Pharmaco-metabolomics
Pharmaco-transcriptomics
Pharmaco-proteomics
Search
Chemical Structure
Molecular Weight
Drug & Food Interactions
Target Sequences
Pharmaco-omics
Advanced Search
MS Search
MS/MS Search
GC/MS Search
1D NMR Search
2D NMR Search
Interaction Checker
Downloads
Data Library
Beta
Academic Downloads
Products
Navigate to
DrugBank.com
to check out our commercial products, use cases and more!
DrugBank For Commercial Research
Drug Datasets
Structured drug data for data science & ML
DrugBank For Clinical Software
Clinical API
Clinical intelligence tool for your software
Features
Drug Search
Customizable drug search options
Drug-Drug Interaction Checker
Search for drug interactions with our API
Drug Allergy
Get drug allergy and cross sensitivities info
US Drug Labels
Integrate drug manufacturer information
About
Help Center
Citing DrugBank
DrugBank Online FAQs
Searching DrugBank
Other Databases
Data Sources
About
About DrugBank Online
DrugBank in Research
Statistics
Blog
Wishart Research Group
Contact Us
Log in
Drugs
Targets
Pathways
Indications
[BLOG]
Precision Medicine in the Genomic Era.
Read More!
Pharmacogenomic Effect/ADR for
Tramadol
(DBSNPE006619)
Documentation
Browse all
Identifier
DBSNPE006619
Drug
Tramadol (DB00193)
Interacting Gene/Enzyme
Cytochrome P450 2D6
Gene Name
CYP2D6
UniProt ID
P10635
Defining Change(s)
Whole-gene deletion
Not Available
Allele Name
CYP2D6*5
Genotype(s)
Not Available
Type(s)
ADR
Inferred
Effect
Groups
Non-functional CYP2D6
Description
Poor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.
References
UltramĀ® (tramadol hydrochloride) tablets[package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; 2016. [
Link
]